TBL2

Across TCGA pan-cancer cohorts, TBL2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TBL2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TBL2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TBL2 expression acts as an unfavorable survival marker.

CCRCC, PDAC, and LUAD are the cancer types where TBL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.586	0.881	<.001	120	view →
PDAC	OS	Median	All	0.447	0.676	.008	9	view →
LUAD	DFS	Median	All	0.688	0.955	.026	5	view →
HNSC	DFS	Median	III,IV	0.937	1.000	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TBL2–CCRCC (DFS)

Open the CCRCC breakdown →